Innoviva, Inc. (NASDAQ:INVA - Get Free Report) major shareholder Alexander J. Denner sold 151,175 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $17.63, for a total value of $2,665,215.25. Following the transaction, the insider now directly owns 7,125,825 shares of the company's stock, valued at approximately $125,628,294.75. The trade was a 2.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Innoviva Stock Performance
INVA opened at $17.59 on Friday. The firm has a market cap of $1.10 billion, a PE ratio of 25.49 and a beta of 0.56. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38. The business has a fifty day simple moving average of $18.03 and a 200-day simple moving average of $18.83. Innoviva, Inc. has a fifty-two week low of $14.33 and a fifty-two week high of $21.28.
Innoviva (NASDAQ:INVA - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.57 earnings per share for the quarter. The business had revenue of $91.81 million during the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. As a group, equities analysts predict that Innoviva, Inc. will post 0.33 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, StockNews.com lowered Innoviva from a "buy" rating to a "hold" rating in a research note on Saturday, February 22nd.
View Our Latest Analysis on INVA
Institutional Investors Weigh In On Innoviva
Several large investors have recently modified their holdings of INVA. US Bancorp DE lifted its holdings in shares of Innoviva by 24.5% in the third quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 566 shares in the last quarter. KBC Group NV lifted its holdings in shares of Innoviva by 73.9% in the fourth quarter. KBC Group NV now owns 4,100 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 1,743 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Innoviva by 75.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,962 shares of the biotechnology company's stock valued at $86,000 after purchasing an additional 2,128 shares in the last quarter. FMR LLC lifted its holdings in shares of Innoviva by 8.2% in the third quarter. FMR LLC now owns 10,119 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 771 shares in the last quarter. Finally, New Age Alpha Advisors LLC purchased a new stake in shares of Innoviva in the fourth quarter valued at $176,000. 99.12% of the stock is owned by institutional investors.
Innoviva Company Profile
(
Get Free Report)
Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
